102460.KS
REYON Pharmaceutical Co., Ltd. [102460.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
102460.KS Stock Summary
Top 10 Correlated ETFs
102460.KS
Top 10 Correlated Stocks
102460.KS
In the News
102460.KS Financial details
Company Rating
Neutral
Market Cap
252.92B
Income
3.58B
Revenue
151.07B
Book val./share
13555.68
Cash/share
1321.68
Dividend
150
Dividend %
0.91%
Employees
463
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
35.04
Forward P/E
-
PEG
-6.83
P/S
2.01
P/B
1.18
P/C
9.99
P/FCF
-13.97
Quick Ratio
-
Current Ratio
2.05
Debt / Equity
0.9
LT Debt / Equity
0.49
-
-
EPS (TTM)
201.71
EPS next Y
-
EPS next Q
-
EPS this Y
-52.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.44%
Revenue last 5Y
2.8%
Revenue Q/Q
3.77%
EPS Q/Q
880.73%
-
-
-
-
SMA20
-14.17%
SMA50
-11.27%
SMA100
-10.89%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
3%
ROC
0.02%
Gross Margin
52%
Oper. Margin
5%
Profit Margin
6%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13540.0-20700.0
52W High
-36.18%
52W Low
-2.44%
RSI
28.18
Rel Volume
0.72
Avg Volume
30.94K
Volume
22.26K
Perf Week
-5.91%
Perf Month
-12.63%
Perf Quarter
-10.56%
Perf Half Y
-15.59%
-
-
-
-
Beta
1.072
-
-
Volatility
290.31%, 1008.48%
Prev Close
-1.27%
Price
13210
Change
2.88%
102460.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 7.65K | 7.64K | 8.06K | 8.68K | 8.24K | |
| Net income per share | 345.53 | 225.75 | 312.5 | 418.73 | 195.38 | |
| Operating cash flow per share | -708.53 | 270.09 | 659.42 | 491.71 | 388.93 | |
| Free cash flow per share | -3.7K | -2.8K | -5.94K | -3.06K | -1.19K | |
| Cash per share | 3.45K | 2.67K | 5.5K | 2.03K | 1.32K | |
| Book value per share | 12.81K | 13.51K | 13.84K | 13.96K | 13.56K | |
| Tangible book value per share | 12.65K | 13.26K | 13.6K | 13.72K | 13.33K | |
| Share holders equity per share | 12.81K | 13.51K | 13.84K | 13.96K | 13.56K | |
| Interest debt per share | 1.96K | 3.5K | 11.71K | 11.85K | 12.18K | |
| Market cap | 269.73B | 376.35B | 629.92B | 389.67B | 306.29B | |
| Enterprise value | 297.57B | 423.59B | 770.49B | 583.83B | 507.24B | |
| P/E ratio | 45.4 | 97.89 | 113.76 | 52.42 | 85.48 | |
| Price to sales ratio | 2.05 | 2.89 | 4.41 | 2.53 | 2.03 | |
| POCF ratio | -22.14 | 81.83 | 53.91 | 44.64 | 42.94 | |
| PFCF ratio | -4.24 | -7.89 | -5.98 | -7.16 | -14.09 | |
| P/B Ratio | 1.22 | 1.64 | 2.57 | 1.57 | 1.23 | |
| PTB ratio | 1.22 | 1.64 | 2.57 | 1.57 | 1.23 | |
| EV to sales | 2.26 | 3.26 | 5.4 | 3.79 | 3.36 | |
| Enterprise value over EBITDA | 23.75 | 46.03 | 74.09 | 48.89 | 77.43 | |
| EV to operating cash flow | -24.42 | 92.1 | 65.94 | 66.88 | 71.11 | |
| EV to free cash flow | -4.68 | -8.88 | -7.32 | -10.73 | -23.33 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Free cash flow yield | -0.24 | -0.13 | -0.17 | -0.14 | -0.07 | |
| Debt to equity | 0.15 | 0.26 | 0.85 | 0.85 | 0.9 | |
| Debt to assets | 0.12 | 0.19 | 0.43 | 0.43 | 0.45 | |
| Net debt to EBITDA | 2.22 | 5.13 | 13.52 | 16.26 | 30.67 | |
| Current ratio | 3.98 | 2.42 | 3.47 | 2.27 | 0.79 | |
| Interest coverage | 67.9 | 23.31 | 51.57 | 60.62 | 9.05 | |
| Income quality | -2.05 | 1.2 | 2.11 | 1.17 | 1.99 | |
| Dividend Yield | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 1.39 | 1.5 | 0.63 | 0.61 | 0.76 | |
| Sales general and administrative to revenue | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Research and developement to revenue | 0.03 | 0.05 | 0.07 | 0.04 | 0.06 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 4.22 | -11.37 | -10.01 | -7.23 | -4.05 | |
| Capex to revenue | -0.39 | -0.4 | -0.82 | -0.41 | -0.19 | |
| Capex to depreciation | -12.57 | -11.46 | -25.08 | -13.93 | -6.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.98K | 8.28K | 9.86K | 11.47K | 7.72K | |
| ROIC | 0.02 | 0.01 | 0.01 | 0.02 | 0 | |
| Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Graham Net | 3.22K | 297.56 | -5.16K | -8.66K | -9.78K | |
| Working capital | 98.55B | 69.02B | 117.3B | 61.05B | -25.79B | |
| Tangible asset value | 217.6B | 225.85B | 241.01B | 243.56B | 244.43B | |
| Net current asset value | 79.39B | 30.25B | -67.94B | -127.92B | -151.34B | |
| Invested capital | 0.15 | 0.26 | 0.85 | 0.85 | 0.9 | |
| Average receivables | 50.35B | 46.06B | 42.4B | 41.88B | 41.4B | |
| Average payables | 3.9B | 4.14B | 4.45B | 4.76B | 6.49B | |
| Average inventory | 22.4B | 26.22B | 27.43B | 28.27B | 32.64B | |
| Days sales outstanding | 133.87 | 123.14 | 104.6 | 101.48 | 96.59 | |
| Days payables outstanding | 26.24 | 26.48 | 27.25 | 24.19 | 40.24 | |
| Days of inventory on hand | 152.93 | 180.68 | 152.26 | 151.98 | 172.91 | |
| Receivables turnover | 2.73 | 2.96 | 3.49 | 3.6 | 3.78 | |
| Payables turnover | 13.91 | 13.78 | 13.39 | 15.09 | 9.07 | |
| Inventory turnover | 2.39 | 2.02 | 2.4 | 2.4 | 2.11 | |
| ROE | 0.03 | 0.02 | 0.02 | 0.03 | 0.01 | |
| Capex per share | -2.99K | -3.07K | -6.6K | -3.56K | -1.57K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.16K | 2.09K | 2.13K | 2.04K | 2.12K | |
| Net income per share | 217.69 | 113.08 | 150.19 | -5.5 | -53.94 | |
| Operating cash flow per share | 235.65 | 184.1 | 272.52 | 37.13 | -20.14 | |
| Free cash flow per share | -253.5 | -343.53 | -85.75 | -377.13 | -322.59 | |
| Cash per share | 2.03K | 1.66K | 2.09K | 1.64K | 1.32K | |
| Book value per share | 13.96K | 13.91K | 14.06K | 13.61K | 13.56K | |
| Tangible book value per share | 13.72K | 13.68K | 13.83K | 13.38K | 13.33K | |
| Share holders equity per share | 13.96K | 13.91K | 14.06K | 13.61K | 13.56K | |
| Interest debt per share | 11.84K | 11.84K | 12.7K | 12.27K | 12.18K | |
| Market cap | 389.67B | 318.31B | 295.58B | 291.81B | 306.29B | |
| Enterprise value | 583.83B | 509.16B | 492.08B | 486.67B | 507.24B | |
| P/E ratio | 25.21 | 39.64 | 27.72 | -722.84 | -77.4 | |
| Price to sales ratio | 10.16 | 8.6 | 7.83 | 7.79 | 7.88 | |
| POCF ratio | 93.15 | 97.39 | 61.1 | 428.51 | -829.14 | |
| PFCF ratio | -86.59 | -52.19 | -194.16 | -42.19 | -51.77 | |
| P/B Ratio | 1.57 | 1.29 | 1.18 | 1.17 | 1.23 | |
| PTB ratio | 1.57 | 1.29 | 1.18 | 1.17 | 1.23 | |
| EV to sales | 15.22 | 13.75 | 13.04 | 13 | 13.06 | |
| Enterprise value over EBITDA | 179.25 | 24.41 | 24.12 | 26.54 | 187.11 | |
| EV to operating cash flow | 139.56 | 155.79 | 101.71 | 714.67 | -1.37K | |
| EV to free cash flow | -129.73 | -83.49 | -323.23 | -70.36 | -85.73 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.02 | -0.02 | |
| Debt to equity | 0.85 | 0.85 | 0.9 | 0.9 | 0.9 | |
| Debt to assets | 0.43 | 0.44 | 0.45 | 0.45 | 0.45 | |
| Net debt to EBITDA | 59.61 | 9.15 | 9.63 | 10.63 | 74.13 | |
| Current ratio | 2.27 | 2.19 | 2.3 | 2.05 | 0.79 | |
| Interest coverage | -33.11 | -217.36 | 132.69 | 1.37 | 33.84 | |
| Income quality | 1.08 | 1.63 | 1.81 | -6.75 | 0.37 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0 | 1.03 | 0 | 0 | |
| Sales general and administrative to revenue | 0.09 | 0.52 | 0.56 | 0.51 | 0.09 | |
| Research and developement to revenue | 0.08 | 0.06 | 0.1 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | -2.08 | -2.87 | -1.31 | -11.16 | 15.02 | |
| Capex to revenue | -0.23 | -0.25 | -0.17 | -0.2 | -0.14 | |
| Capex to depreciation | -7.26 | -7.76 | -4.97 | -6.24 | -5.15 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.27K | 5.95K | 6.89K | 1.3K | 4.06K | |
| ROIC | 0.01 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | 0 | 0 | |
| Graham Net | -8.66K | -9.05K | -9.41K | -9.49K | -9.78K | |
| Working capital | 61.05B | 52.55B | 60.8B | 51.93B | -25.79B | |
| Tangible asset value | 243.56B | 242.81B | 245.45B | 245.39B | 244.43B | |
| Net current asset value | -127.92B | -136.78B | -141.39B | -148.42B | -151.34B | |
| Invested capital | 0.85 | 0.85 | 0.9 | 0.9 | 0.9 | |
| Average receivables | 42.49B | 40.85B | 38.67B | 38.96B | 39.72B | |
| Average payables | 5.5B | 4.08B | 4.72B | 6.46B | 7.51B | |
| Average inventory | 30.95B | 29.26B | 30.19B | 31.81B | 33.41B | |
| Days sales outstanding | 100.47 | 94.48 | 91.71 | 94.86 | 92.6 | |
| Days payables outstanding | 22.29 | 18.73 | 31.55 | 32.23 | 36.94 | |
| Days of inventory on hand | 140.03 | 158.03 | 165.9 | 149.09 | 158.75 | |
| Receivables turnover | 0.9 | 0.95 | 0.98 | 0.95 | 0.97 | |
| Payables turnover | 4.04 | 4.81 | 2.85 | 2.79 | 2.44 | |
| Inventory turnover | 0.64 | 0.57 | 0.54 | 0.6 | 0.57 | |
| ROE | 0.02 | 0.01 | 0.01 | 0 | 0 | |
| Capex per share | -489.14 | -527.63 | -358.28 | -414.26 | -302.45 |
102460.KS Frequently Asked Questions
What is REYON Pharmaceutical Co., Ltd. stock symbol ?
REYON Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 102460.KS
What is REYON Pharmaceutical Co., Ltd. stock quote today ?
REYON Pharmaceutical Co., Ltd. stock price is $13210 today.
Is REYON Pharmaceutical Co., Ltd. stock public?
Yes, REYON Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 30.94K
- Market Capitalization 252.92B
- Employee 463
- CEO Ms. Soon-Ock Jung
- Headquarters Seoul,KR
- IPO Date 2010-06-10
-
Website
https://reyonpharm.co.kr 
REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
